Compare TransMedics Group Inc (TMDX) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 18.9× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 2,892,221). Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| TMDX | VCSH | |
|---|---|---|
Market Cap | $2.74B | $51.90B |
Volume | 949,331 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $150.42 | $80.20 |
52-Week Low | $61.99 | $77.03 |
Typical Hold Time | 24 Days | 52 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $77.34 with a slight 0.09% daily gain. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights its competitive 4.5% dividend yield and low 0.03% expense ratio, though some analysts note tight credit spreads and downgrade it to 'Hold'. The fund's short 2.7-year duration minimizes interest rate risk but carries corporate credit exposure.
The ETF offers a higher yield than treasury alternatives but faces headwinds from limited price appreciation potential amid rising rates and compressed spreads. Key risks include credit deterioration and institutional selling. Analyst sentiment is mixed, balancing yield appeal against near-term unattractive entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
